Pfizer has advised Save Our Sons Duchenne Foundation today, that they have initiated a Phase 1b clinical trial for its mini-dystrophin gene therapy candidate, PF-06939926, in Duchenne, with the first boy receiving an infusion of the mini-dystrophin gene on March 22 at Duke University Medical Center.
There will be an anticipated 4 additional sites in the US that will be screening to enrol more patients, and early data is expected in mid 2019 one full year from their initial dosing.
Save Our Sons Duchenne Foundation are thrilled to hear this news and are excited to see the advancement of Pfizer’s gene therapy trial. Although this trial is not currently recruiting in Australia we are working tirelessly to secure more trials and will be meeting with Pfizer in late May in Boston to discuss the Australian clinical trial capacity and the Australian Duchenne community.
If you or a family member has Duchenne or Becker PLEASE join our patient registry www.duchenneconnectaustralia.org.au to help with planning new trials.
Follow the link for the official press release HERE